These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Oliver RT; Gallagher CJ Cancer Surv; 1995; 23():191-207. PubMed ID: 7621458 [TBL] [Abstract][Full Text] [Related]
25. Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes. Berg A; Dahl AA; Bruland ØS; Bjøro T; Aanensen MS; Fosså SD Prostate Cancer Prostatic Dis; 2009; 12(3):269-76. PubMed ID: 19290019 [TBL] [Abstract][Full Text] [Related]
26. Current controversies in the treatment of high-risk prostate cancer. Mitchell RE; Chang SS Curr Opin Urol; 2008 May; 18(3):263-8. PubMed ID: 18382235 [TBL] [Abstract][Full Text] [Related]
27. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. Kassouf W; Tanguay S; Aprikian AG J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822 [TBL] [Abstract][Full Text] [Related]
28. Management of hormone refractory prostate cancer. Lin AM; Small EJ Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361 [TBL] [Abstract][Full Text] [Related]
29. Overview of Canadian trials in hormonally resistant prostate cancer. Moore MJ; Tannock IF Semin Oncol; 1996 Dec; 23(6 Suppl 14):15-9. PubMed ID: 8996579 [TBL] [Abstract][Full Text] [Related]